Five China medical injection molders flagged for documentation gaps

An editorial review profiles five separately registered injection molding companies in China that publicly describe medical or medical-adjacent work, and it measures them against the documentation buyers need for regulated medical plastic parts. The review says molding capability alone is not enough; suppliers also need proof of validation, traceability, cleanroom control and change management at the site level.

Why it matters: - Medical buyers need more than a capable molder; they need evidence that the supplier can support regulated production, validation and traceability. - The review says general injection molding quality and medical-device documentation are separate issues. - The FDA Quality Management System Regulation, which incorporates ISO 13485:2016 by reference, became effective on Feb. 2, 2026. - Grand View Research put the global medical injection molding market at about $27.32 billion in 2025 and projected $38.32 billion by 2030. - Asia Pacific accounted for 41.9% of 2025 revenue, according to the same market research.

What happened: - An editorial review published Oct. 14, 2026, profiled five independently registered injection molding companies operating in China with publicly available materials tied to medical molding, tooling or medical device manufacturing. - The companies are Xiamen DTG Tech Co., Ltd.; Dongguan Yize Mould Co., Ltd.; Wuxi Senjun Precision Injection Molding Co., Ltd.; Nolato Precision Injection Molding Components (Beijing) Co., Ltd.; and Huimei Medical Devices (Suzhou) Co., Ltd. - The review says the list is not a ranking or an endorsement. - The review was based on company websites, product pages and regulatory publications from the U.S. Food and Drug Administration and the International Organization for Standardization. - The review did not include factory audits, official business registry verification, certificate validation or product testing.

The details: - Xiamen DTG Tech Co., Ltd. says it was established in 2002 and offers precision mold design, tool manufacturing, prototype development, plastic injection molding and mass production. - DTG reports a 2,500 m² facility, about 80 employees, a 25-engineer R&D team and annual production capacity of 47,881 units. - DTG says 100% of output is exported to the United States, Europe and India. - DTG public materials list medical products among the applicable industries for custom injection molded plastic parts. - DTG says its precision components use ABS, PC, POM, nylon and engineering plastics, with dimensional control based on engineering drawings and quality control through dimensional inspection and first article inspection. - DTG also lists plastic housings and insert injection molded parts among its product lines. - DTG public material on medical and healthcare applications describes parts that support device structure and protect internal modules and sensors. - DTG’s published capabilities include polishing, painting, printing and assembly support. - The review says ISO 13485 certification, cleanroom classification, sterilization capability, biocompatibility validation and FDA registration were not documented in the reviewed materials for DTG. - Dongguan Yize Mould Co., Ltd. has public product pages that describe medical molds and injection molding, but the review says the name is used by more than one legal entity in public records. - The review says the specific company responsible for medical tooling must be identified before qualification. - For Yize, the article says certification status, achievable precision, founding year and the scope of the medical mold offering were not verified. - Wuxi Senjun Precision Injection Molding Co., Ltd. has public business descriptions referencing medical plastic parts and consumables together with precision mold injection. - The review says medical capability published for other sites in a wider group should not automatically be attributed to the Wuxi legal entity. - Nolato Precision Injection Molding Components (Beijing) Co., Ltd. appears in Nolato group careers material as a precision injection molding legal entity in Beijing. - The review says the listing confirms the entity and molding focus, but not specific medical device product families, materials or validation services at the Beijing site. - Huimei Medical Devices (Suzhou) Co., Ltd. has public registration information indicating a business scope covering medical devices, life science consumables, plastic parts and molds. - The review says similar names are registered separately and capabilities tied to international partners or affiliates should not be merged into the Suzhou entity. - The FDA training material cited in the review says process validation is required when a process cannot be fully verified by later inspection and testing, and names injection molding as an example. - The FDA inspection guidance cited in the review lists molding, sterilization operations, environmental control systems such as cleanrooms and testing methods among processes that may require validation. - The review says none of the five companies’ public pages established installation, operational and performance qualification documentation for a specific site. - The review says none of the five profiles confirmed a certified cleanroom at the entity and site level. - The review says none of the five companies had publicly verifiable details on resin substitution, mold modification or process parameter change control. - The review says DTG documents dimensional inspection and first article inspection for precision components and describes dimensional measurement and visual inspection for medical and healthcare applications. - The review says the other four companies need site-level confirmation for critical dimension inspection, traceability, assembly and project communication practices.

Between the lines: - The review suggests Chinese molders may have public medical positioning without having the documentation package buyers need for regulated work. - A medical resin label alone is not proof of finished-device biocompatibility. - Cleanroom molding is not the same as product sterility. - Capability claims from a parent group or related brand should not be assumed to apply to a specific legal entity or site. - The article frames documentation scope, not production capacity, as the key differentiator for medical sourcing decisions.

What's next: - Buyers are being told to verify the exact legal entity and site address before requesting quotes. - The review recommends asking for current quality management system certificates and checking the scope against the required molding, assembly and testing work. - Buyers should request process validation protocols, acceptance criteria, parameter controls, deviation handling and revalidation triggers where validation applies. - Buyers should ask for material grade data sheets, batch documentation and biocompatibility evidence tied to the finished device. - Buyers requiring cleanroom work should request classification details, environmental monitoring records and controlled-area qualification documents. - Buyers should confirm first article inspection reports, calibration status and traceability records for critical dimensions before awarding medical work. - The review says suppliers in this space will likely be judged more on documentation than molding capacity as regulatory demands tighten.

The bottom line: - In China’s medical injection molding market, public capability claims are only the starting point; site-specific proof of quality systems, validation and change control is what qualifies a supplier for regulated medical programs. - The review cites a company contact line and website for DTG, but says none of the companies should be assumed to hold specific medical certifications or registrations unless verified directly.